[Surgery in patients with severe or inhibitory hemophilia A under prevention injection of emicizumab].

Objective: To determine the features of preoperative hemostatic therapy and laboratory control in patients with severe and inhibitory forms of hemophilia A under preventive treatment by FVIII.

Material And Methods: Four patients with severe and inhibitory forms of hemophilia A underwent surgery between 2021 and 2022. All patients received Emicizumab (the first monoclonal drug for «non-factor» therapy of hemophilia) for prevention of specific hemorrhagic signs of hemophilia.

[Therapy with high-doses of antithrombin III in patients with septic shock and agranulocytosis].

Objective: The aim of the study was to assess efficacy of high-doses ofantithrombin 111 (AT) for treatment of septic shock in patients with an agranulocytosis.

Design: Prospective, controlled study.

Patients: 29 patients from 18 to 74 years old, with blood diseases complicated with septic shock Dates of study: from 2006 to 2012.

[Acute abdominal syndrome in blood system diseases].

Aim: To define an optimal diagnostic and therapeutic algorithm when the acute abdominal syndrome occurs in hematological patients.

Materials And Methods: The results of 145 emergency surgeries made in 2006-2008 for acute abdominal syndrome were studied in patients with blood system diseases.

Results: Clinical manifestations of acute abdominal syndrome emerge in 1-1.